Start date: 01 September 2022
End date: 31 August 2027
The main aim of the REGeRNA project is to develop a synthetic messenger RNA capable of reinducing cardiomyocyte proliferation in patients suffering from heart failure.
Heart failure (HF) is a major health problem worldwide because of the high number of patients and the related costs.
Current treatments are not consistently efficacious and fail to address the major underlying cause of Heart failure: the massive loss of cardiomyocytes in damaged regions.
REGeRNA has been designed to address this issue by leveraging advances in synthetic mRNAs and their lipid nanoparticle (LNP)-based carriers to generate a construct able to reactivate mechanisms mediating cardiomyocyte proliferation in development but which are shut-down shortly after birth. REGeRNA is organised in 6 work packages that follow a roadmap towards endogenous heart repair.